{"filing":{"accession_number":"0001493152-26-039785","cik":"0001679628","ticker":"JUNS","company_name":"JUPITER NEUROSCIENCES, INC.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-21","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1679628/000149315226039785/form8-k.htm"},"events":[{"id":29067,"run_id":26596,"accession_number":"0001493152-26-039785","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses two equity issuances: (1) an unregistered sale of 107,920 shares to Yorkville under a Standby Equity Purchase Agreement for $851,194 (Item 3.02), and (2) a registered direct offering of 307,692 shares for approximately $2.0 million (Item 8.01/press release). Both represent dilutive equity issuances to raise capital. Item 3.02 explicitly covers unregistered sales under Section 4(a)(2) and Regulation D, which is the core dilutive_issuance category. The registered offering, while technically registered, is still a material capital raise that dilutes existing shareholders.","company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31217,"accession_number":"0001493152-26-039785","item_number":"3.02","item_title":"Unregistered Sales of","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two equity issuances: (1) an unregistered sale of 107,920 shares to Yorkville under a Standby Equity Purchase Agreement for $851,194 (Item 3.02), and (2) a registered direct offering of 307,692 shares for approximately $2.0 million (Item 8.01/press release). Both represent dilutive equity issuances to raise capital. Item 3.02 explicitly covers unregistered sales under Section 4(a)(2) and Regulation D, which is the core dilutive_issuance category. The registered offering, while technically registered, is still a material capital raise that dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:07:19.680971+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31217,"accession_number":"0001493152-26-039785","item_number":"3.02","item_title":"Unregistered Sales of","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two equity issuances: (1) an unregistered sale of 107,920 shares to Yorkville under a Standby Equity Purchase Agreement for $851,194 (Item 3.02), and (2) a registered direct offering of 307,692 shares for approximately $2.0 million (Item 8.01/press release). Both represent dilutive equity issuances to raise capital. Item 3.02 explicitly covers unregistered sales under Section 4(a)(2) and Regulation D, which is the core dilutive_issuance category. The registered offering, while technically registered, is still a material capital raise that dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:07:19.680971+00:00","company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","filing_date":"2026-08-24"}]}